Diametric Capital LP Acquires New Shares in Atyr PHARMA INC (NASDAQ:ATYR)

Diametric Capital LP bought a new position in Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 29,812 shares of the company’s stock, valued at approximately $108,000.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Atyr PHARMA by 467.8% in the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company’s stock worth $646,000 after buying an additional 147,092 shares in the last quarter. American Century Companies Inc. bought a new stake in Atyr PHARMA during the 4th quarter worth approximately $319,000. Farther Finance Advisors LLC purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $88,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the 4th quarter valued at $39,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Atyr PHARMA currently has a consensus rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Stock Performance

Shares of NASDAQ ATYR opened at $2.96 on Thursday. The stock has a market cap of $263.02 million, a price-to-earnings ratio of -3.15 and a beta of 0.98. The stock’s 50-day moving average is $3.61 and its 200 day moving average is $3.21. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, sell-side analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.